Product/Composition:- | LamotriginevDispersible tablets |
---|---|
Strength:- | XR: 25 mg, 50 mg, 100 mg, 200 mg; IR: 25 mg, 100 mg, 200 mg, 300 mg |
Form:- | Tablets(IR & ER) |
Reference Brands:- | Lamictal, Lamictal XR(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Lamotrigine dispersible tablets, both IR and ER, inhibit voltage-gated sodium channels, stabilizing neuronal membranes and reducing excitability. They effectively control seizures and stabilize mood in bipolar disorder. Benefits include flexible dosing, rapid absorption, ease of swallowing, improved adherence, and better symptom management, supporting long-term epilepsy and bipolar treatment.
Lamotrigine dispersible tablets, available as immediate-release (IR) and extended-release (ER), are approved in the US by the FDA and in the EU via EMA for epilepsy and bipolar disorder management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial data and manufacturing processes, while the EMA ensures compliance with regional safety and quality regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance facilitates timely approvals, supports safe use, and promotes worldwide availability of lamotrigine dispersible tablets, improving long-term patient care globally.